Articles

UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
female (900) 900
humans (883) 883
science & technology (818) 818
life sciences & biomedicine (783) 783
oncology (431) 431
middle aged (416) 416
ovarian cancer (412) 412
ovarian neoplasms - genetics (379) 379
ovarian neoplasms - pathology (348) 348
adult (343) 343
fallopian tube neoplasms - pathology (303) 303
obstetrics & gynecology (293) 293
fallopian tube neoplasms - genetics (291) 291
aged (287) 287
fallopian tube (277) 277
cancer (262) 262
mutation (241) 241
tumors (241) 241
pathology (194) 194
fallopian tubes - pathology (187) 187
genes, brca1 (183) 183
ovariectomy (180) 180
biological and medical sciences (168) 168
genes, brca2 (165) 165
surgery (164) 164
fallopian tubes (162) 162
medical sciences (162) 162
genetic predisposition to disease (152) 152
cystadenocarcinoma, serous - pathology (143) 143
ovarian neoplasms - prevention & control (137) 137
genetic aspects (134) 134
risk factors (132) 132
gynecology. andrology. obstetrics (124) 124
cystadenocarcinoma, serous - genetics (118) 118
immunohistochemistry (113) 113
research (112) 112
animals (110) 110
fallopian tubes - surgery (109) 109
health aspects (107) 107
obstetrics and gynecology (107) 107
female genital diseases (102) 102
breast cancer (101) 101
ovarian carcinoma (101) 101
ovarian neoplasms - metabolism (101) 101
ovarian neoplasms - surgery (100) 100
neoplasm staging (97) 97
retrospective studies (92) 92
fallopian tubes - metabolism (90) 90
breast neoplasms - genetics (89) 89
prognosis (89) 89
gynecology (88) 88
fallopian tube neoplasms - surgery (87) 87
female genital diseases and pregnancy complications (86) 86
analysis (85) 85
brca (82) 82
aged, 80 and over (80) 80
chemotherapy (80) 80
carcinoma (79) 79
hematology, oncology and palliative medicine (79) 79
abridged index medicus (75) 75
carcinoma, ovarian epithelial (75) 75
care and treatment (74) 74
gene expression (73) 73
neoplasm grading (72) 72
peritoneal neoplasms - pathology (72) 72
brca1 protein - genetics (70) 70
cell biology (68) 68
fallopian tube neoplasms - metabolism (68) 68
germ-line mutation (68) 68
peritoneal neoplasms - genetics (68) 68
diagnosis (67) 67
fallopian tube neoplasms - diagnosis (67) 67
ovarian neoplasms - drug therapy (67) 67
salpingectomy (67) 67
women (67) 67
endocrine system diseases (65) 65
medicine & public health (65) 65
metastasis (64) 64
mice (63) 63
tumor suppressor protein p53 - genetics (63) 63
gene expression regulation, neoplastic (62) 62
hysterectomy (62) 62
prevention (62) 62
ovarian neoplasms - diagnosis (61) 61
brca2 protein - genetics (60) 60
brca1 (59) 59
cell line, tumor (57) 57
carcinoma in situ - pathology (56) 56
human genetics (56) 56
neoplasms, glandular and epithelial - pathology (56) 56
ovary - pathology (55) 55
fallopian tube neoplasms - prevention & control (54) 54
treatment outcome (54) 54
gene mutations (52) 52
cystadenocarcinoma, serous - metabolism (51) 51
epithelium (50) 50
fallopian tube neoplasms - drug therapy (50) 50
medicine (50) 50
ovary (49) 49
patients (49) 49
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (998) 998
French (10) 10
German (6) 6
Polish (4) 4
Spanish (4) 4
Chinese (2) 2
Czech (2) 2
Dutch (2) 2
Hebrew (1) 1
Hungarian (1) 1
Italian (1) 1
Japanese (1) 1
Portuguese (1) 1
Russian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial
by Swisher, Elizabeth M, Dr Prof and Lin, Kevin K, PhD and Oza, Amit M, Prof and Scott, Clare L, PhD and Giordano, Heidi, MA and Sun, James, PhD and Konecny, Gottfried E, MD and Coleman, Robert L, Prof and Tinker, Anna V, MD and O'Malley, David M, MD and Kristeleit, Rebecca S, MD and Ma, Ling, MD and Bell-McGuinn, Katherine M, MD and Brenton, James D, Prof and Cragun, Janiel M, MD and Oaknin, Ana, MD and Ray-Coquard, Isabelle, Prof and Harrell, Maria I, PhD and Mann, Elaina, MS and Kaufmann, Scott H, Prof and Floquet, Anne, MD and Leary, Alexandra, MD and Harding, Thomas C, PhD and Goble, Sandra, MS and Maloney, Lara, BA and Isaacson, Jeff, PhD and Allen, Andrew R, MD and Rolfe, Lindsey, MBChB and Yelensky, Roman, PhD and Raponi, Mitch, PhD and McNeish, Iain A, Prof
The lancet oncology, ISSN 1470-2045, 2016, Volume 18, Issue 1, pp. 75 - 87
Hematology, Oncology and Palliative Medicine | Life Sciences & Biomedicine | Oncology | Science & Technology | Prognosis | Prospective Studies | Follow-Up Studies | Humans | Middle Aged | Ovarian Neoplasms - pathology | Salvage Therapy | Neoplasm Recurrence, Local - drug therapy | Germ-Line Mutation - genetics | Neoplasm Recurrence, Local - pathology | Ovarian Neoplasms - genetics | Neoplasms, Glandular and Epithelial - genetics | Peritoneal Neoplasms - drug therapy | Fallopian Tube Neoplasms - genetics | Female | Antineoplastic Agents - pharmacology | Poly(ADP-ribose) Polymerases - chemistry | Ovarian Neoplasms - drug therapy | Platinum - pharmacology | Fallopian Tube Neoplasms - drug therapy | Peritoneal Neoplasms - pathology | Neoplasms, Glandular and Epithelial - pathology | Fallopian Tube Neoplasms - pathology | Survival Rate | Poly(ADP-ribose) Polymerase Inhibitors - therapeutic use | BRCA1 Protein - genetics | International Agencies | Peritoneal Neoplasms - genetics | Neoplasms, Glandular and Epithelial - drug therapy | Carcinoma, Ovarian Epithelial | Indoles - therapeutic use | Neoplasm Recurrence, Local - genetics | Aged | Neoplasm Staging | BRCA2 Protein - genetics | Drug Resistance, Neoplasm - drug effects | Sugars | Monosaccharides | Ovarian cancer | Analysis | Carcinoma | Cancer | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Data set for reporting of ovary, fallopian tube and primary peritoneal carcinoma: recommendations from the International Collaboration on Cancer Reporting (ICCR)
by McCluggage, W. Glenn and Judge, Meagan J and Clarke, Blaise A and Davidson, Ben and Gilks, C. Blake and Hollema, Harry and Ledermann, Jonathan A and Matias-Guiu, Xavier and Mikami, Yoshiki and Stewart, Colin J. R and Vang, Russell and Hirschowitz, Lynn and International Collaboration on Cancer Reporting
Modern pathology, ISSN 0893-3952, 08/2015, Volume 28, Issue 8, pp. 1101 - 1122
Life Sciences & Biomedicine | Pathology | Science & Technology | Predictive Value of Tests | Humans | Ovarian Neoplasms - pathology | Immunohistochemistry - standards | Carcinoma - chemistry | Peritoneal Neoplasms - chemistry | Ovarian Neoplasms - genetics | Peritoneal Neoplasms - drug therapy | Neoplasm Grading | Fallopian Tube Neoplasms - chemistry | Fallopian Tube Neoplasms - genetics | Female | Molecular Diagnostic Techniques - standards | Neoadjuvant Therapy | Chemotherapy, Adjuvant | Carcinoma - pathology | Ovarian Neoplasms - drug therapy | Fallopian Tube Neoplasms - drug therapy | Carcinoma - drug therapy | Peritoneal Neoplasms - pathology | Pathology, Clinical - standards | Diagnosis, Differential | Ovarian Neoplasms - chemistry | Biopsy - standards | Biomarkers, Tumor - analysis | Carcinoma - surgery | Peritoneal Neoplasms - surgery | Fallopian Tube Neoplasms - pathology | Fallopian Tube Neoplasms - surgery | Peritoneal Neoplasms - genetics | Carcinoma - genetics | Research Design - standards | Biomarkers, Tumor - genetics | Neoplasm Staging | Ovarian Neoplasms - surgery | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas
by Pennington, Kathryn P and Walsh, Tom and Harrell, Maria I and Lee, Ming K and Pennil, Christopher C and Rendi, Mara H and Thornton, Anne and Norquist, Barbara M and Casadei, Silvia and Nord, Alexander S and Agnew, Kathy J and Pritchard, Colin C and Scroggins, Sheena and Garcia, Rochelle L and King, Mary-Claire and Swisher, Elizabeth M
Clinical cancer research, ISSN 1078-0432, 2014, Volume 20, Issue 3, pp. 764 - 775
Life Sciences & Biomedicine | Oncology | Science & Technology | Gastroenterology. Liver. Pancreas. Abdomen | Pharmacology. Drug treatments | Biological and medical sciences | Multiple tumors. Solid tumors. Tumors in childhood (general aspects) | Medical sciences | Antineoplastic agents | Tumors | Abdomen | Homologous Recombination - drug effects | Humans | Middle Aged | Gene Expression Regulation, Neoplastic | Carcinoma - mortality | Antineoplastic Agents - therapeutic use | Ovarian Neoplasms - mortality | Peritoneal Neoplasms - mortality | Ovarian Neoplasms - genetics | Platinum Compounds - therapeutic use | Drug Resistance, Neoplasm - genetics | Peritoneal Neoplasms - drug therapy | Fallopian Tube Neoplasms - mortality | Peritoneal Neoplasms - genetics | Fallopian Tube Neoplasms - genetics | Aged, 80 and over | Homologous Recombination - genetics | Adult | Carcinoma - genetics | Female | Aged | Mutation | Ovarian Neoplasms - drug therapy | Fallopian Tube Neoplasms - drug therapy | Index Medicus | somatic mutations | Ovarian carcinoma | homologous recombination | next-generation sequencing | survival
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: Evidence for a causal relationship
by Kindelberger, David W and Lee, Yonghee and Miron, Alexander and Hirsch, Michelle S and Feltmate, Colleen and Medeiros, Fabiola and Callahan, Michael J and Garner, Elizabeth O and Gordon, Robert W and Birch, Chandler and Berkowitz, Ross S and Muto, Michael G and Crum, Christopher P
The American journal of surgical pathology, ISSN 0147-5185, 02/2007, Volume 31, Issue 2, pp. 161 - 169
Serous carcinoma | BRCA | Fallopian tube neoplasms | Ovarian neoplasms | Intraepithelial carcinoma | Pathology | Life Sciences & Biomedicine | Surgery | Science & Technology | Biological and medical sciences | Investigative techniques, diagnostic techniques (general aspects) | Medical sciences | Pathology. Cytology. Biochemistry. Spectrometry. Miscellaneous investigative techniques | Humans | Cystadenocarcinoma, Serous - metabolism | Ovarian Neoplasms - pathology | Cystadenocarcinoma, Serous - genetics | Cystadenocarcinoma, Serous - pathology | Ovarian Neoplasms - genetics | Carcinoma in Situ - genetics | Fallopian Tube Neoplasms - genetics | Female | Ovarian Neoplasms - metabolism | Neoplasms, Second Primary - genetics | Pelvic Neoplasms - pathology | Peritoneal Neoplasms - pathology | Carcinoma in Situ - pathology | Pelvic Neoplasms - genetics | Tumor Suppressor Protein p53 - metabolism | Fallopian Tube Neoplasms - pathology | Genes, p53 - genetics | Neoplasms, Second Primary - metabolism | Peritoneal Neoplasms - genetics | Peritoneal Neoplasms - metabolism | Fallopian Tube Neoplasms - metabolism | Mutation | Carcinoma in Situ - metabolism | Precancerous Conditions | Neoplasms, Second Primary - pathology | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation
by Finch, Amy P M and Finch, Amy P. M and Lubinski, Jan and Lubinski, Jan and Møller, Pål and Møller, Pål and Singer, Christian F and Singer, Christian F and Karlan, Beth and Karlan, Beth and Senter, Leigha and Senter, Leigha and Rosen, Barry and Rosen, Barry and Maehle, Lovise and Maehle, Lovise and Ghadirian, Parviz and Ghadirian, Parviz and Cybulski, Cezary and Cybulski, Cezary and Huzarski, Tomasz and Huzarski, Tomasz and Eisen, Andrea and Eisen, Andrea and Foulkes, William D and Foulkes, William D and Kim-Sing, Charmaine and Kim-Sing, Charmaine and Ainsworth, Peter and Ainsworth, Peter and Tung, Nadine and Tung, Nadine and Lynch, Henry T and Lynch, Henry T and Neuhausen, Susan and Neuhausen, Susan and Metcalfe, Kelly A and Metcalfe, Kelly A and Thompson, Islay and Thompson, Islay and Murphy, Joan and Murphy, Joan and Sun, Ping and Sun, Ping and Narod, Steven A and Narod, Steven A
Journal of clinical oncology, ISSN 0732-183X, 2014, Volume 32, Issue 15, pp. 1547 - 1553
Life Sciences & Biomedicine | Oncology | Science & Technology | Ovariectomy - adverse effects | Age Factors | Humans | Middle Aged | Ovarian Neoplasms - pathology | Ovarian Neoplasms - mortality | North America | Incidence | Ovarian Neoplasms - genetics | Time Factors | Fallopian Tube Neoplasms - genetics | Aged, 80 and over | Adult | Female | Registries | Surveys and Questionnaires | Odds Ratio | Peritoneal Neoplasms - pathology | Fallopian Tube Neoplasms - prevention & control | Genetic Predisposition to Disease | Ovarian Neoplasms - prevention & control | Risk Assessment | Europe | Risk Factors | Kaplan-Meier Estimate | Proportional Hazards Models | Fallopian Tube Neoplasms - pathology | Treatment Outcome | Peritoneal Neoplasms - prevention & control | Peritoneal Neoplasms - mortality | BRCA1 Protein - genetics | Ovariectomy - mortality | Phenotype | Fallopian Tube Neoplasms - mortality | Peritoneal Neoplasms - genetics | Aged | Mutation | BRCA2 Protein - genetics | Index Medicus | Gync21 | Bios4 | Bc3 | ORIGINAL REPORTS | Gync15
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Poly(ADP)-Ribose Polymerase Inhibition: Frequent Durable Responses in BRCA Carrier Ovarian Cancer Correlating With Platinum-Free Interval
by Peter C. Fong and Timothy A. Yap and David S. Boss and Craig P. Carden and Marja Mergui-Roelvink and Charlie Gourley and Jacques De Greve and Jan Lubinski and Susan Shanley and Christina Messiou and Roger A'Hern and Andrew Tutt and Alan Ashworth and John Stone and James Carmichael and Jan H.M. Schellens and Johann S. de Bono and Stan B. Kaye
Journal of clinical oncology, ISSN 0732-183X, 05/2010, Volume 28, Issue 15, pp. 2512 - 2519
Life Sciences & Biomedicine | Oncology | Science & Technology | Gynecology. Andrology. Obstetrics | Biological and medical sciences | Medical sciences | Tumors | Female genital diseases | Humans | Middle Aged | Ovarian Neoplasms - pathology | Drug Resistance, Neoplasm | Dose-Response Relationship, Drug | Ovarian Neoplasms - genetics | Peritoneal Neoplasms - drug therapy | Fallopian Tube Neoplasms - genetics | Aged, 80 and over | Genes, BRCA2 | Germ-Line Mutation | Adult | Female | Genes, BRCA1 | Ovarian Neoplasms - drug therapy | Fallopian Tube Neoplasms - drug therapy | Peritoneal Neoplasms - pathology | Pharmacogenetics | Fallopian Tube Neoplasms - enzymology | Fallopian Tube Neoplasms - pathology | Piperazines - therapeutic use | Piperazines - adverse effects | Poly(ADP-ribose) Polymerase Inhibitors | Ovarian Neoplasms - enzymology | Peritoneal Neoplasms - enzymology | Phthalazines - therapeutic use | Poly(ADP-ribose) Polymerases - genetics | Peritoneal Neoplasms - genetics | Cell Line, Tumor | Aged | Neoplasm Staging | Phthalazines - adverse effects | Cohort Studies | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation — An NRG Oncology/Gynecologic Oncology Group study
by Coleman, Robert L and Sill, Michael W and Bell-McGuinn, Katherine and Aghajanian, Carol and Gray, Heidi J and Tewari, Krishnansu S and Rubin, Steven C and Rutherford, Thomas J and Chan, John K and Chen, Alice and Swisher, Elizabeth M
Gynecologic oncology, ISSN 0090-8258, 2015, Volume 137, Issue 3, pp. 386 - 391
Hematology, Oncology and Palliative Medicine | Obstetrics and Gynecology | BRCA1, BRCA2 mutation | Toxicity | Veliparib | PARP inhibitor | Phase II trial | Ovarian cancer | Oncology | Life Sciences & Biomedicine | Obstetrics & Gynecology | Science & Technology | Humans | Middle Aged | Neoplasm Recurrence, Local - drug therapy | Ovarian Neoplasms - genetics | BRCA1 Protein - genetics | Neoplasms, Glandular and Epithelial - genetics | Peritoneal Neoplasms - drug therapy | Peritoneal Neoplasms - genetics | Fallopian Tube Neoplasms - genetics | Neoplasms, Glandular and Epithelial - drug therapy | Aged, 80 and over | Carcinoma, Ovarian Epithelial | Genes, BRCA2 | Germ-Line Mutation | Adult | Female | Neoplasm Recurrence, Local - genetics | Aged | Genes, BRCA1 | Benzimidazoles - adverse effects | Ovarian Neoplasms - drug therapy | BRCA2 Protein - genetics | Benzimidazoles - therapeutic use | Fallopian Tube Neoplasms - drug therapy | Medical research | Cancer patients | Care and treatment | Gene mutations | Analysis | Medicine, Experimental | Genetic aspects | Cancer | Chemotherapy | Clinical trials | Index Medicus | toxicity | BRCA2 mutation | ovarian cancer | veliparib | BRCA1
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text A genetically engineered ovarian cancer mouse model based on fallopian tube transformation mimics human high‐grade serous carcinoma development
by Sherman‐Baust, Cheryl A and Kuhn, Elisabetta and Valle, Blanca L and Shih, Ie‐Ming and Kurman, Robert J and Wang, Tian‐Li and Amano, Tomokazu and Ko, Minoru SH and Miyoshi, Ichiro and Araki, Yoshihiko and Lehrmann, Elin and Zhang, Yongqing and Becker, Kevin G and Morin, Patrice J
The Journal of pathology, ISSN 0022-3417, 07/2014, Volume 233, Issue 3, pp. 228 - 237
transgenic mouse model | ovarian cancer | fallopian tube | intraepithelial carcinoma | Top2a | p53 | Pathology | Oncology | Life Sciences & Biomedicine | Science & Technology | Neoplasms, Cystic, Mucinous, and Serous - metabolism | Adenocarcinoma - pathology | Cell Proliferation | Humans | Gene Expression Regulation, Neoplastic | Ovarian Neoplasms - pathology | Tumor Suppressor Protein p53 - genetics | DNA-Binding Proteins - metabolism | Fallopian Tubes - pathology | Neoplasms, Cystic, Mucinous, and Serous - genetics | Ovarian Neoplasms - genetics | Poly-ADP-Ribose Binding Proteins | Adenocarcinoma - metabolism | Neoplasm Grading | Cell Transformation, Neoplastic - genetics | Antigens, Neoplasm - metabolism | Biomarkers, Tumor - metabolism | Female | Adenocarcinoma - genetics | Ovarian Neoplasms - metabolism | Disease Models, Animal | Glycoproteins - genetics | Antigens, Neoplasm - genetics | DNA Topoisomerases, Type II - metabolism | Promoter Regions, Genetic | Neoplasms, Cystic, Mucinous, and Serous - pathology | Antigens, Polyomavirus Transforming - genetics | Antigens, Polyomavirus Transforming - metabolism | Neoplasm Invasiveness | Mice, Inbred C57BL | Tumor Suppressor Protein p53 - metabolism | Mice, Transgenic | DNA-Binding Proteins - genetics | Cell Transformation, Neoplastic - metabolism | Disease Progression | Fallopian Tubes - metabolism | Animals | Genetic Engineering | DNA Topoisomerases, Type II - genetics | Biomarkers, Tumor - genetics | Mice | Cell Transformation, Neoplastic - pathology | Immunohistochemistry | DNA microarrays | Carcinoma | Analysis | Genetically modified organisms | Genetic engineering | Tumor proteins | Ovarian cancer | Cancer | Medical research | Rodents | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text BRCA Mutation Frequency and Patterns of Treatment Response in BRCA Mutation–Positive Women With Ovarian Cancer: A Report From the Australian Ovarian Cancer Study Group
by Kathryn Alsop and Sian Fereday and Cliff Meldrum and Anna deFazio and Catherine Emmanuel and Joshy George and Alexander Dobrovic and Michael J. Birrer and Penelope M. Webb and Colin Stewart and Michael Friedlander and Stephen Fox and David Bowtell and Gillian Mitchell
Journal of clinical oncology, ISSN 0732-183X, 07/2012, Volume 30, Issue 21, pp. 2654 - 2663
Life Sciences & Biomedicine | Oncology | Science & Technology | Gynecology. Andrology. Obstetrics | Biological and medical sciences | Medical sciences | Tumors | Female genital diseases | Medical History Taking | Recurrence | Prospective Studies | Humans | Middle Aged | Ovarian Neoplasms - pathology | Drug Resistance, Neoplasm | Cystadenocarcinoma, Serous - genetics | Cystadenocarcinoma, Serous - drug therapy | Case-Control Studies | Ovarian Neoplasms - genetics | Peritoneal Neoplasms - drug therapy | Neoplasm Grading | Fallopian Tube Neoplasms - genetics | Aged, 80 and over | Genes, BRCA2 | Germ-Line Mutation | Adult | Female | Genes, BRCA1 | Ovarian Neoplasms - drug therapy | Fallopian Tube Neoplasms - drug therapy | Carcinoma - drug therapy | Carcinoma, Endometrioid - genetics | Kaplan-Meier Estimate | Mutation Rate | Treatment Outcome | Carcinoma, Endometrioid - drug therapy | Australia - epidemiology | Ovarian Neoplasms - epidemiology | Disease-Free Survival | Point Mutation | Breast Neoplasms - genetics | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Peritoneal Neoplasms - genetics | Carcinoma - genetics | Aged | Platinum Compounds - administration & dosage | Neoplasm Staging | Adenocarcinoma, Clear Cell - genetics | Adenocarcinoma, Clear Cell - drug therapy | Cohort Studies | Index Medicus | Original Reports | Gynecologic Cancer | Gync21 | Gync15
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights